bobapp安卓推动神经制药宣布上市计划

(环球通讯社)- Impel NeuroPharma, Inc.(纳斯达克:bobapp安卓生物制药公司IMPL (IMPL)今日宣布,已开始承销300万股普通股。该公司目前处于商业阶段,正在为患有严重未满足医疗需求疾bob体育客户端操作病的患者开发变动性疗法,最初的重点是中枢神经系统。所有的普通股都是由Impel发行的。此外,Impel还计划授予承销商一项30天的选择权,在扣除承销折扣和佣金的基础上,以发行价再购买至多45万股普通股。

考恩和古根海姆证券(Guggenheim Securities)将共同担任此次ipo的账簿管理人。Wedbush PacGrow担任首席经理。

拟发行只能通过招股说明书进行。有关此次发行的初步招股说明书副本可从以下地方获得:Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717,或通过电话(833)297-2926或电子邮件()PostSaleManualRequests@broadridge.com;注意事项:股权辛迪加部门,330 Madison Avenue, New York, NY 10017,或通过电话(212)518-9544或电子邮件GSEquityProspectusDelivery@guggenheimpartners.com

有关拟出售这些证券的注册声明已提交给美国证券交易委员会(SEC),但尚未生效。该证券在登记声明生效前不得出售,也不得接受要约购买。本新闻稿中不构成要约出售或要约收购的恳求,也不得有任何出售这些证券在任何州或管辖权的报价,之前征集、或销售非法登记或资格的证券法下任何这样的状态或管辖。

BOBios下载关于推动Nebobapp安卓uroPharma:

bobapp安卓Impel NeuroPharma, Inc.是一家处于商业阶段的生物制药公司,为患有严重未满足医疗需求疾病的患者开发变革性疗法,最初专注于中枢神经系统。bob体育客户端操作Impel提供并正在开发其专有的精密嗅觉递送(POD)疗法®)具有完善治疗方法的技术。除了TRUDHESA™(甲磺酸双氢麦角胺)鼻喷雾剂,这是批准在美国有或无先兆偏头痛的急性治疗成人,推动也在开发INP105风潮和侵略性的急性治疗自闭症患者,和INP107在帕金森病发作。

关于前瞻性陈述的警告
This press release contains “forward-looking” statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the terms of the proposed public offering, including Impel’s expectations with respect to granting the underwriters a 30-day option to purchase additional shares, and the completion, timing and size of the proposed public offering. Forward-looking statements can be identified by words such as: “believe,” “may,” “will,” “potentially,” “estimate,” “continue,” “anticipate,” “intend,” “could,” “would,” “project,” “plan,” “expect” or the negative or plural of these words or similar expressions. These statements are subject to numerous risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Many of these risks are described in greater detail in Impel’s filings with the SEC. Any forward-looking statements in this press release speak only as of the date of this press release. Impel assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

联系

投资者关系:
克里蒂娜塔特拉里亚
斯特恩投资者关系
电话:(1)212-362-1200
电子邮件:christina.tartaglia@sternir.com

媒体关系:
Melyssa Weible
长生不老药公共关系
电话:(1)201-723-5805
电子邮件:mweible@elixirhealthpr.com.